Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 24:13:1142041.
doi: 10.3389/fcimb.2023.1142041. eCollection 2023.

Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications

Yan Sun  1 , Shouyang Gao  2 , Cong Ye  2 , Weiliang Zhao  1
Affiliations
Review

Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications

Yan Sun et al. Front Cell Infect Microbiol. .

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine diseases in women of childbearing age that leads to menstrual disorders and infertility. The pathogenesis of PCOS is complex and has not yet been fully clarified. Gut microbiota is associated with disorders of lipid, glucose, and steroid hormone metabolish. A large body of studies demonstrated that gut microbiota could regulate the synthesis and secretion of insulin, and affect androgen metabolism and follicle development, providing us a novel idea for unravelling the pathogenesis of PCOS. The relationship between gut microbiota and the pathogenesis of PCOS is particularly important. This study reviewed recent research advances in the roles of gut microbiota in the occurrence and development of PCOS. It is expected to provide a new direction for the treatment of PCOS based on gut microbiota.

Keywords: Polycystic ovary syndrome; gut microbiota; infertility; insulin; women.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Ali D. E. S., Shah M., Ali A., Malik M. O., Rehman F., Badshah H., et al. . (2019). Treatment with metformin and combination of metformin plus pioglitazone on serum levels of IL-6 and IL-8 in polycystic ovary syndrome: A randomized clinical trial. Hormone. Metab. Res. 51, 714–722. doi: 10.1055/a-1018-9606 - DOI - PubMed
    1. Amisi C. A. (2022). Markers of insulin resistance in polycystic ovary syndrome women: An update. World J. Diabetes 13, 129–149. doi: 10.4239/wjd.v13.i3.129 - DOI - PMC - PubMed
    1. Artar G., Tas B., Turan G., Uckan H. H. (2022). Evaluation of androgen-dependent skin findings of polycystic ovary syndrome (PCOS). Gynecol. Endocrinol., 1–5. doi: 10.1080/09513590.2022.2162496 - DOI - PubMed
    1. Barroso A., Santos-Marcos J. A., Perdices-Lopez C., Vega-Rojas A., Sanchez-Garrido M. A., Krylova Y., et al. . (2020). Neonatal exposure to androgens dynamically alters gut microbiota architecture. J. Endocrinol. 247, 69–85. doi: 10.1530/JOE-20-0277 - DOI - PubMed
    1. Bednarz K., Kowalczyk K., Cwynar M., Czapla D., Czarkowski W., Kmita D., et al. . (2022). The role of glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int. J. Mol. Sci. 23, 4334. doi: 10.3390/ijms23084334 - DOI - PMC - PubMed

Publication types